Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Boule Diagnostics ABCHIX:BOULS 47 EV-to-EBIT is 16.88 as of Jul. 14, 2026, which is 2% below its 10-year median of 17.17. GuruFocus rates CHIX:BOULS with a GF Score™ of 47/100 and a GF Value™ of kr49.42. The stock has 2 warning signs investors should review. Among 466 Medical Devices & Instruments companies, Boule Diagnostics AB ranks better than 57.3% on this metric.
The historical rank and industry rank for Boule Diagnostics AB's EV-to-EBIT or its related term are showing as below:
CHIX:BOULs'
s EV-to-EBIT Range Over the Past 10 Years
Min: -180.91 Med: 17.17 Max: 168.6
Current: 16.88
During the past 13 years, the highest EV-to-EBIT of Boule Diagnostics AB was 168.60. The lowest was -180.91. And the median was 17.17.
CHIX:BOULs's EV-to-EBIT is ranked better than 57.3% of 466
companies
in the Medical Devices & Instruments industry
Industry Median: 18.74
vs CHIX:BOULs: 16.88
Boule Diagnostics AB (CHIX:BOULs) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Boule Diagnostics AB's Enterprise Value for the quarter that ended in Mar. 2026 was kr1,224.8 Mil.
Boule Diagnostics AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr20.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boule Diagnostics AB EV-to-EBIT Related Terms
Boule Diagnostics AB EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Boule Diagnostics AB's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:BOULS vs ABT, SYK, MDT: EV-to-EBIT Comparison
For the Medical Devices subindustry, Boule Diagnostics AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boule Diagnostics AB EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Boule Diagnostics AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Boule Diagnostics AB's EV-to-EBIT falls into.
Boule Diagnostics AB's current Enterprise Value is kr351.1 Mil.
Boule Diagnostics AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr20.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boule Diagnostics AB (CHIX:BOULS) has a EV-to-EBIT of 16.88 as of Jul. 14, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Boule Diagnostics AB and its competitors. This is near median its historical median of 17.17. According to the industry distribution chart, Boule Diagnostics AB ranks #199 out of 466 companies in the Medical Devices & Instruments industry, placing it in the top 42.7%.
Is Boule Diagnostics AB's EV-to-EBIT too high?
Boule Diagnostics AB's current EV-to-EBIT of 16.88 is near median its 10-year median of 17.17. The Medical Devices & Instruments industry median EV-to-EBIT is 18.74. Boule Diagnostics AB's value of 16.88 is 9.9% below this industry median. Based on the distribution chart, Boule Diagnostics AB ranks #199 out of 466 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Boule Diagnostics AB has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Boule Diagnostics AB's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Boule Diagnostics AB ranks #199 out of 466 companies for EV-to-EBIT. This puts Boule Diagnostics AB in the upper half of its industry. The industry median EV-to-EBIT is 18.74. Boule Diagnostics AB's value of 16.88 is 9.9% below this benchmark. While the company's 10-year median is 17.17 vs. the industry median of 18.74, Boule Diagnostics AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.74, based on 466 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boule Diagnostics AB's current EV-to-EBIT of 16.88 is 9.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Boule Diagnostics AB and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boule Diagnostics AB's current EV-to-EBIT is 16.88, which is near median its own 10-year median of 17.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boule Diagnostics AB stock overvalued right now?
Boule Diagnostics AB (CHIX:BOULS) has a current EV-to-EBIT of 16.88. The stock's GF Value™ is kr49.42, compared to a current price of kr26.30 — trading 46.8% below its estimated fair value. The current EV-to-EBIT is 16.88, which is near median its 10-year median of 17.17 and 9.9% below the Medical Devices & Instruments industry median of 18.74. Boule Diagnostics AB's overall GF Score™ is 47/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Boule Diagnostics AB (CHIX:BOULS), the current EV-to-EBIT is 16.88 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boule Diagnostics AB (CHIX:BOULS) Overvalued in 2026?
Based on GuruFocus' analysis, Boule Diagnostics AB stock appears to be undervalued.
The current stock price of kr26.30 is trading 46.8% below its estimated GF Value™ of kr49.42.
Key valuation signals for CHIX:BOULS:
EV-to-EBIT: 16.88 (near median its 10-year median of 17.17)
GF Value™: kr49.42 vs. price of kr26.30 (46.8% below fair value)
Industry Position: 9.9% below the Medical Devices & Instruments median (#199 of 466)
No single metric tells the full story. See the CHIX:BOULS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. the company operating through two complementary business segments: Diagnostics and OEM CDS. Through its subsidiaries, the company operates in USA ,Asia, Eastern Europe, Latin America Western Europe and Africa / Middle East. The majority revenue is generated from Asia.
47GF Score
Get the complete analysis for CHIX:BOULS
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BOULS has been successfully added to your 
